Join our daily newsletter At The Bell to receive exclusive market insights
- Prescient Therapeutics (PTX) is granted a key US patent for its OmniCAR universal immune receptor (UIR) platform
- The new patent protects Prescient’s two-part covalent binding system known as SpyTag and SpyCatcher, which forms a key component of the UIR platform
- As such, Prescient says this patent is a key plank in the protection of its OmniCAR product
- The patent provides protection in the world’s largest healthcare market until at least 2039
- Shares in Prescient Therapeutics are up 6.06 per cent and trading at 18 cents at 10:21 am AEST
Prescient Therapeutics (PTX) has been granted a key US patent for its OmniCAR universal immune receptor (UIR) platform.
The US patent protects a key component of Prescient’s UIR platform: a two-part covalent binding system dubbed “SpyTag” and “SpyCatcher”, developed by Oxford University. The University of Pennsylvania applied this unique binding system to cell therapy, which is described in the patent which has been exclusively licensed to Prescient.
Prescient Managing Director and CEO Steven Yatomi-Clarke said this patent is a key plank in the protection of the OmniCAR platform.
“Prescient continues to bolster the protection of this innovative platform through the development of new intellectual property as we progress our three exciting OmniCAR programs through pre-clinical development and towards the clinic,” Steven Yatomi-Clarke said.
The OmniCAR platform is designed to create next-generation modular cell therapies that are controllable, flexible and adaptable.
Prescient believes OmniCAR is the only known UIR system employing covalent binding — a strong chemical bond.
The new US patent provides protection in the world’s largest healthcare market until at least 2039.
Shares in Prescient Therapeutics were up 6.06 per cent and trading at 18 cents at 10:21 am AEST.
